Syneron's Breakthrough Technologies Take Center Stage at 31st Annual Conference of the American Society of Laser Medicine and Surgery

By Syneron Medical Ltd., PRNE
Monday, April 4, 2011

YOKNEAM, Israel, April 5, 2011 - Syneron Medical Ltd. (NASDAQ: ELOS),, the global
leader in the medical aesthetic device marketplace, further solidified its
commitment to science, results and earning the trust of aesthetic physicians
with a strong showing of Syneron and Candela's innovative technologies at the
31st Annual Conference of the American Society for Laser Medicine and Surgery
(ASLMS) in Grapevine, Texas.

"Our unique combination of cutting-edge science, life-enhancing clinical
results and high level of trust within the global aesthetic community
continues to solidify our position at the forefront of this industry," said
Louis P. Scafuri, Chief Executive Officer of Syneron. "We value the
opportunity that conferences such as ASLMS provide to showcase our ability to
consistently create and commercialize scientific advances in innovative
medical and aesthetic solutions that meet our customers' needs."

At the ASLMS conference, Syneron and Candela featured a family of newly
available breakthrough products, including:

    -- GentleLASE(R) PRO High Speed Hair Removal System, the Company's latest
       and most advanced aesthetic laser. Building on its highly successful
       hair removal product line, the next-generation GentleLASE Pro has
       been improved to meet the demands of physicians by giving them faster
       treatment times, greater treatment versatility and enhanced ease of

According to Thomas E. Rohrer, MD, Skincare Physicians of Chestnut Hill,
, "We have 20 to 30 different lasers, and a lot of these do hair removal,
but we keep ending back at the GentleLASE. It continues to be my go-to laser
for hair removal, no matter how many hair removal lasers we try."

    -- ePrime(TM) Energy-Based Dermal Remodeling System, which was featured
       in an experts panel session that was attended by more than 220
       physicians interested in learning about this revolutionary new
       dimension in facial enhancement. Bypassing the epidermis, ePrime is
       the first minimally invasive aesthetic device to precisely target and
       deliver measured radio frequency (RF) energy directly into the deep
       dermis to stimulate the growth of collagen and elastin for noticeable
       improvement of skin tone and volume in a single treatment.

    -- elure(TM) Advanced Skin Lightening Technology(TM), the first and only
       topical skin lightening product that improves appearance by
       temporarily reducing melanin, the pigment that accumulates in the skin
       to cause a darkened or uneven skin tone. Using this novel natural
       enzyme called Melanozyme(TM), the elure system delivers improvement in
       skin appearance, creating healthier, brighter and younger-looking skin
       in 30 days, with excellent tolerability.

    -- CO2RE(TM) Complete CO2 Resurfacing System, a versatile CO2 system that
       offers all current aesthetic CO2 treatment methodologies plus the
       unique Fusion fractional mode that has the ability to treat both
       superficial and deep skin layers simultaneously with precision-control
       over the intensity, pattern and depth of ablation. The introduction of
       CO2RE gives customers more choices and greater flexibility to meet
       their individual practice needs without the requirement of multiple
       hand pieces or optical spots.

    -- eMatrix(R) Sublative Rejuvenation(R), the world's first bipolar
       RF-only technology for energy-based facial rejuvenation. The device
       delivers high-intensity dermal impact with less epidermal ablation,
       resulting in minimal patient downtime. Due to the minimal epidermal
       disruption, eMatrix treats skin texture and tone without skin color
       limitations, making it an ideal rejuvenation choice for patients with
       darker skin tones.

In addition to displaying its latest world-class aesthetic technologies,
Syneron had nearly 20 abstracts presented at the meeting, highlighting the
Company's strong commitment to science, which forms the building blocks to
innovate new technology.

For more information, visit

About Syneron Medical Ltd.

Syneron Medical Ltd. - a company devoted to real technology, real science
and real results - is the leading global aesthetic device company with a
comprehensive product portfolio and a global distribution footprint. The
Company's technology enables physicians to provide advanced solutions for a
broad range of medical-aesthetic applications including body contouring, hair
removal, wrinkle reduction, rejuvenation of the skin's appearance through the
treatment of superficial benign vascular and pigmented lesions, and the
treatment of acne, leg veins and cellulite. The Company sells its products
under two distinct brands, Syneron and Candela. With its innovative approach
to aesthetic treatments, Syneron has now entered into one of the largest
in-demand applications, skin lightening. Founded in 2000, the corporate, R&D,
and manufacturing headquarters for Syneron Medical Ltd. are located in
Israel. Syneron also has R&D and manufacturing operations in the US. The
company markets and services and supports its products in 86 countries. It
has offices in North America, France, Germany, Italy, Portugal, Spain, UK,
Australia, China, Japan, and Hong Kong and distributors worldwide.

Additional information can be found at


Any statements contained in this document regarding future expectations,
beliefs, goals, plans or prospects constitute forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995.
Further, any statements that are not statements of historical fact (including
statements containing "believes," "anticipates," "plans," "expects," "may,"
"will," "would," "intends," "estimates" and similar expressions) should also
be considered to be forward-looking statements. There are a number of
important factors that could cause actual results or events to differ
materially from those indicated by such forward-looking statements, including
the risk that the businesses of Syneron and Candela may not be integrated
successfully; the risk that the merger transaction with Candela may involve
unexpected costs or unexpected liabilities; the risk that synergies from the
merger transaction may not be fully realized or may take longer to realize
than expected; the risk that disruptions from the merger transaction make it
more difficult to maintain relationships with customers, employees, or
suppliers; as well as the risks set forth in Syneron Medical Ltd.'s most
recent Annual Report on Form 20-F, and the other factors described in the
filings that Syneron Medical Ltd. makes with the SEC from time to time. If
one or more of these factors materialize, or if any underlying assumptions
prove incorrect, Syneron Medical Ltd.'s actual results, performance or
achievements may vary materially from any future results, performance or
achievements expressed or implied by these forward-looking statements.

In addition, the statements in this document reflect the expectations and
beliefs of Syneron Medical Ltd. as of the date of this document. Syneron
Medical Ltd. anticipates that subsequent events and developments will cause
its expectations and beliefs to change. However, while Syneron Medical Ltd.
may elect to update these forward-looking statements publicly in the future,
it specifically disclaims any obligation to do so. The forward-looking
statements of Syneron Medical Ltd. do not reflect the potential impact of any
future dispositions or strategic transactions that may be undertaken. These
forward-looking statements should not be relied upon as representing Syneron
Medical Ltd.'s views as of any date after the date of this document.

    Jane Smith
    Director of Marketing Communications, Candela Corporation
    Office: +1-508-358-7637 Ext. 247; Mobile: +1-978-314-1053

    Erin Carney
    Senior Account Executive, Ruder Finn
    Office: +1-212-593-6358; Mobile: +1-917-692-9166


will not be displayed